{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=72", "query": { "condition": "Skin Disorders", "page": 72 }, "page_size": 10 }, "pagination": { "page": 72, "page_size": 10, "total_count": 16135, "total_pages": 1614, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=73&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=71&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T14:09:48.696Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00379197", "title": "Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "naltrexone", "type": "DRUG" }, { "name": "PET scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2006-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379197" }, { "nct_id": "NCT00192517", "title": "Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "MEDI-522", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2003-12", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2009-04-03", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 18, "location_summary": "Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00192517" }, { "nct_id": "NCT06130540", "title": "Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Giant Cell Arteritis", "Polymyalgia Rheumatica" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "50 Years to 100 Years" }, "enrollment_count": 65, "start_date": "2024-03-27", "completion_date": "2025-04-02", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 8, "location_summary": "Boca Raton, Florida • Zephyrhills, Florida • Willowbrook, Illinois + 5 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Zephyrhills", "state": "Florida" }, { "city": "Willowbrook", "state": "Illinois" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06130540" }, { "nct_id": "NCT00979550", "title": "The Effects of Aldara as an Adjunct to Laser Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Port Wine Stains" ], "interventions": [ { "name": "Imiquimod", "type": "DRUG" }, { "name": "non-medicated petroleum cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Vasconez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "2 Years to 60 Years" }, "enrollment_count": 7, "start_date": "2008-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00979550" }, { "nct_id": "NCT01449591", "title": "Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Erythemato-telangiectatic Rosacea" ], "interventions": [ { "name": "BFH772 1% ointment", "type": "DRUG" }, { "name": "Vehicle ointment", "type": "DRUG" }, { "name": "Noritate® 1% cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2011-09", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 6, "location_summary": "Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Paramus", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449591" }, { "nct_id": "NCT01796197", "title": "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mastectomy", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-08", "completion_date": "2026-01", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01796197" }, { "nct_id": "NCT00287482", "title": "Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "Essiac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Women and Infants Hospital of Rhode Island", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 20, "start_date": "2005-10", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2007-02-12", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287482" }, { "nct_id": "NCT03212079", "title": "Physical Activities by Technology Help (PATH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Prostate Cancer", "Lung Cancer", "Colorectal Cancer", "Cervical Cancer", "Oral Cancer" ], "interventions": [ { "name": "Mycoach Smart Text", "type": "BEHAVIORAL" }, { "name": "MyCoach on Amazon Alexa", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2017-04-03", "completion_date": "2018-06-30", "has_results": false, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03212079" }, { "nct_id": "NCT04564443", "title": "A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Foot Ulcer", "Diabetic Foot" ], "interventions": [ { "name": "Medaxis Debritom+", "type": "OTHER" }, { "name": "Sharp Surgical Debridement", "type": "OTHER" }, { "name": "Additional Outer Dressing Application", "type": "OTHER" }, { "name": "Offloading", "type": "OTHER" }, { "name": "Fibracol Wound Dressing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medaxis, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2020-09-11", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 6, "location_summary": "San Francisco, California • South Miami, Florida • Frederick, Maryland + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Youngstown", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564443" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-11-07T14:09:48.696Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" } ] }